CV Therapeutics Overview
- Year Founded
-
1990
- Status
-
Acquired/Merged
- Employees
-
550
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.4B
CV Therapeutics General Information
Description
Developer and marketer of novel, small molecule drugs for the treatment of cardiovascular diseases. The company's major products were Ranexa (ranolazine extended-release tablets) and Lexiscan (regadenoson).
Contact Information
Corporate Office
- 3172 Porter Dr
- Palo Alto, CA 94304
- United States
Corporate Office
- 3172 Porter Dr
- Palo Alto, CA 94304
- United States
CV Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 17-Apr-2009 | $1.4B | Completed | Generating Revenue | ||
| 8. PIPE | 16-Apr-2008 | Completed | Generating Revenue | |||
| 7. PIPE | 18-Apr-2006 | Completed | Generating Revenue | |||
| 6. PIPE | 01-Aug-2000 | Completed | Generating Revenue | |||
| 5. IPO | 06-Oct-1999 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series G) | 01-May-1996 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series E) | 01-Nov-1995 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series D) | 01-Apr-1994 | $16.5M | $23.4M | Completed | Generating Revenue | |
| 1. Later Stage VC (Series C) | 01-Jul-1993 | $6.88M | $6.88M | Completed | Generating Revenue |
CV Therapeutics Signals
CV Therapeutics Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Acqua Wellington | PE/Buyout | Minority | ||
| Alloy Ventures | Venture Capital | Minority | ||
| Asset Management Ventures | Venture Capital | Minority | ||
| Axon Capital | Hedge Fund | Minority | ||
| Azimuth Opportunity | Investment Bank | Minority |
CV Therapeutics FAQs
-
When was CV Therapeutics founded?
CV Therapeutics was founded in 1990.
-
Where is CV Therapeutics headquartered?
CV Therapeutics is headquartered in Palo Alto, CA.
-
What is the size of CV Therapeutics?
CV Therapeutics has 550 total employees.
-
What industry is CV Therapeutics in?
CV Therapeutics’s primary industry is Drug Discovery.
-
Is CV Therapeutics a private or public company?
CV Therapeutics is a Private company.
-
What is the current valuation of CV Therapeutics?
The current valuation of CV Therapeutics is .
-
What is CV Therapeutics’s current revenue?
The current revenue for CV Therapeutics is .
-
How much funding has CV Therapeutics raised over time?
CV Therapeutics has raised $609M.
-
Who are CV Therapeutics’s investors?
Acqua Wellington, Alloy Ventures, Asset Management Ventures, Axon Capital, and Azimuth Opportunity are 5 of 16 investors who have invested in CV Therapeutics.
-
When was CV Therapeutics acquired?
CV Therapeutics was acquired on 17-Apr-2009.
-
Who acquired CV Therapeutics?
CV Therapeutics was acquired by Gilead.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process